Skip to main content
Journal cover image

Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.

Publication ,  Journal Article
Satlin, MJ; van Duin, D; Tamma, PD; Lodise, TP; Van Tyne, D; Rodvold, KA; Rouphael, N; Evans, SR; Fowler, VG; Hamasaki, T; Patel, R; Baum, K ...
Published in: Clin Infect Dis
October 16, 2023

Addressing the treatment and prevention of antibacterial-resistant gram-negative bacterial infections is a priority area of the Antibacterial Resistance Leadership Group (ARLG). The ARLG has conducted a series of observational studies to define the clinical and molecular global epidemiology of carbapenem-resistant and ceftriaxone-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii, with the goal of optimizing the design and execution of interventional studies. One ongoing ARLG study aims to better understand the impact of fluoroquinolone-resistant gram-negative gut bacteria in neutropenic patients, which threatens to undermine the effectiveness of fluoroquinolone prophylaxis in these vulnerable patients. The ARLG has conducted pharmacokinetic studies to inform the optimal dosing of antibiotics that are important in the treatment of drug-resistant gram-negative bacteria, including oral fosfomycin, intravenous minocycline, and a combination of intravenous ceftazidime-avibactam and aztreonam. In addition, randomized clinical trials have assessed the safety and efficacy of step-down oral fosfomycin for complicated urinary tract infections and single-dose intravenous phage therapy for adult patients with cystic fibrosis who are chronically colonized with P. aeruginosa in their respiratory tract. Thus, the focus of investigation in the ARLG has evolved from improving understanding of drug-resistant gram-negative bacterial infections to positively affecting clinical care for affected patients through a combination of interventional pharmacokinetic and clinical studies, a focus that will be maintained moving forward.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

October 16, 2023

Volume

77

Issue

Suppl 4

Start / End Page

S305 / S313

Location

United States

Related Subject Headings

  • Pseudomonas aeruginosa
  • Microbiology
  • Microbial Sensitivity Tests
  • Leadership
  • Humans
  • Gram-Negative Bacterial Infections
  • Gram-Negative Bacteria
  • Fosfomycin
  • Fluoroquinolones
  • Drug Resistance, Multiple, Bacterial
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Satlin, M. J., van Duin, D., Tamma, P. D., Lodise, T. P., Van Tyne, D., Rodvold, K. A., … Antibacterial Resistance Leadership Group, . (2023). Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. Clin Infect Dis, 77(Suppl 4), S305–S313. https://doi.org/10.1093/cid/ciad547
Satlin, Michael J., David van Duin, Pranita D. Tamma, Thomas P. Lodise, Daria Van Tyne, Keith A. Rodvold, Nadine Rouphael, et al. “Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.Clin Infect Dis 77, no. Suppl 4 (October 16, 2023): S305–13. https://doi.org/10.1093/cid/ciad547.
Satlin MJ, van Duin D, Tamma PD, Lodise TP, Van Tyne D, Rodvold KA, et al. Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S305–13.
Satlin, Michael J., et al. “Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.Clin Infect Dis, vol. 77, no. Suppl 4, Oct. 2023, pp. S305–13. Pubmed, doi:10.1093/cid/ciad547.
Satlin MJ, van Duin D, Tamma PD, Lodise TP, Van Tyne D, Rodvold KA, Rouphael N, Evans SR, Fowler VG, Hamasaki T, Patel R, Komarow L, Baum K, Souli M, Schwager N, Bonomo RA, Doi Y, Antibacterial Resistance Leadership Group. Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S305–S313.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

October 16, 2023

Volume

77

Issue

Suppl 4

Start / End Page

S305 / S313

Location

United States

Related Subject Headings

  • Pseudomonas aeruginosa
  • Microbiology
  • Microbial Sensitivity Tests
  • Leadership
  • Humans
  • Gram-Negative Bacterial Infections
  • Gram-Negative Bacteria
  • Fosfomycin
  • Fluoroquinolones
  • Drug Resistance, Multiple, Bacterial